Zevra Therapeutics urges shareholders to vote for all director nominees

Zevra Therapeutics announced it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with the Company’s 2023 Annual Meeting of Stockholders, which is scheduled to take place on April 25, 2023. Shareholders of record as of March 1, 2023, will be entitled to vote at the meeting. In conjunction with the definitive proxy filing, the Company has mailed a letter to Zevra shareholders recommending they vote "FOR" the Company’s three directors up for re-election on the WHITE proxy card – Richard Pascoe, David Tierney, M.D., and Christopher Posner. "We believe Zevra is a stronger company today, with the right leadership and strategy in place for growth and value creation," said Matthew Plooster, Chairman. "Many of the recent changes we’ve implemented in continuing to transform into a commercially focused rare disease therapeutics company are the direct result of shareholder feedback and their constructive input toward achieving our mutual goal of enhancing value. We listened, and with our new strategic purpose, we believe we are well positioned to execute on numerous value-creating milestone opportunities anticipated for 2023 and beyond."